Puma Biotechnology Inc (NYSE:PBYI)‘s stock had its “buy” rating reiterated by investment analysts at Citigroup Inc. in a research note issued to investors on Monday, May 22nd, Marketbeat.com reports. They currently have a $88.00 price objective on the biopharmaceutical company’s stock. Citigroup Inc.’s price target points to a potential upside of 12.97% from the company’s previous close.
Several other research analysts have also issued reports on PBYI. Royal Bank of Canada cut their price target on Puma Biotechnology from $48.00 to $17.00 and set a “sector perform” rating on the stock in a report on Thursday, March 2nd. Credit Suisse Group restated an “outperform” rating and issued a $58.00 target price on shares of Puma Biotechnology in a report on Tuesday, April 18th. Stifel Nicolaus restated a “buy” rating and issued a $88.00 target price on shares of Puma Biotechnology in a report on Wednesday, April 19th. Finally, Zacks Investment Research upgraded Puma Biotechnology from a “hold” rating to a “buy” rating and set a $36.00 target price on the stock in a report on Tuesday, May 16th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $86.94.
Puma Biotechnology (NYSE PBYI) traded down 0.76% during midday trading on Monday, reaching $77.90. 1,418,413 shares of the company traded hands. The company has a 50-day moving average price of $57.52 and a 200-day moving average price of $41.84. Puma Biotechnology has a 12-month low of $27.64 and a 12-month high of $92.00. The company’s market cap is $2.88 billion.
Puma Biotechnology (NYSE:PBYI) last announced its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($1.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.06) by $0.09. On average, analysts predict that Puma Biotechnology will post ($8.50) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Puma Biotechnology Inc (PBYI) Earns “Buy” Rating from Citigroup Inc.” was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.chaffeybreeze.com/2017/06/16/puma-biotechnology-inc-pbyi-earns-buy-rating-from-citigroup-inc-2-updated-updated.html.
In other Puma Biotechnology news, major shareholder Adage Capital Partners Gp, L.L sold 247,260 shares of the firm’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $80.32, for a total value of $19,859,923.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 1,990,088 shares of company stock valued at $157,553,113 over the last three months. Company insiders own 22.70% of the company’s stock.
Several institutional investors have recently made changes to their positions in the stock. Credit Suisse AG boosted its position in shares of Puma Biotechnology by 97.9% in the first quarter. Credit Suisse AG now owns 82,644 shares of the biopharmaceutical company’s stock valued at $3,075,000 after buying an additional 40,890 shares during the period. Redmile Group LLC boosted its position in shares of Puma Biotechnology by 33.7% in the first quarter. Redmile Group LLC now owns 1,725,414 shares of the biopharmaceutical company’s stock valued at $64,185,000 after buying an additional 435,274 shares during the period. Endurant Capital Management LP acquired a new stake in Puma Biotechnology during the first quarter valued at about $1,101,000. Boxer Capital LLC acquired a new stake in Puma Biotechnology during the first quarter valued at about $3,720,000. Finally, Weiss Multi Strategy Advisers LLC acquired a new stake in Puma Biotechnology during the first quarter valued at about $335,000. Institutional investors own 80.98% of the company’s stock.
About Puma Biotechnology
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with MarketBeat.com's FREE daily email newsletter.